Literature DB >> 1419299

Biological characterisation of primary and metachronous lesions in breast cancer patients.

R Silvestrini1, B Valentinis, M G Daidone, G Di Fronzo, D Coradini, B Salvadori.   

Abstract

Proliferative activity, evaluated as [3H]thymidine labelling index ([3H]dT LI), and hormone receptors were determined on 97 primary breast cancers and on metachronous lesions from the same patient. Overall, the [3H]dT LI of metachronous lesions was significantly higher than that of the primary tumour (P = 0.003). Hormone receptor profiles of the two lesions were similar in about 75% of the cases; disagreements were mainly due to a disappearance of hormone receptors in metachronous lesions. In contralateral tumours, [3H]dT LI and hormone receptors were unrelated to those of the relative primary lesion. In this series of relapsing patients, [3H]dT LI was unrelated to hormone receptor status in the primary tumour, but it was higher in the metachronous lesions from patients with hormone receptor-negative primary tumours. For patients given no systemic therapy between surgery and relapse, the time to develop local-regional recurrences or contralateral tumours was inversely related to the [3H]dT LI of the metachronous lesions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419299     DOI: 10.1016/0959-8049(92)90249-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  2 in total

1.  Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma.

Authors:  A Bonetti; M Zaninelli; S Rodella; A Molino; L Sperotto; Q Piubello; F Bonetti; R Nortilli; M Turazza; G L Cetto
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Expression of high-affinity 67-kDa laminin receptors in primary breast cancers and metachronous metastatic lesions or contralateral cancers.

Authors:  M G Daidone; R Silvestrini; E Benini; W F Grigioni; A D'Errico
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.